AbbVie presents detailed Phase 1 data for ABBV-295 at EASD 2026
AbbVie presented detailed Phase 1 data for ABBV-295, a long-acting amylin analog, describing favorable tolerability and a pharmacokinetic profile at EASD 2026.
AbbVie presented detailed Phase 1 data for ABBV-295, a long-acting amylin analog, describing favorable tolerability and a pharmacokinetic profile at EASD 2026.